The Prognostic Value of Histidine-Rich Glycoprotein RNA in Breast Tissue Using Unmodified Gold Nanoparticles Assay
- 202 Downloads
The aim of is this study is to explore the role of tissue histidine-rich glycoprotein (HRG) RNA as a promising clinically useful biomarker for breast cancer patients prognosis using nanogold assay. Expression of the HRG RNA was assessed by gold nanoparticles and conventional RT-PCR after purification by magnetic nanoparticles in breast tissue samples. The study included 120 patients, 60 of which were histologically proven breast carcinoma cases, 30 had benign breast lesions and 30 were healthy individuals who had undergone reductive plastic surgery. ER, PR and HER2 status were also investigated. The prognostic significance of tissue HRG RNA expression in breast cancer was explored. The magnetic nanoparticles coated with specific thiol modified oligonucleotide probe were used successfully in purification of HRG RNA from breast tissue total RNAs with satisfactory yield. The developed HRG AuNPs assay had a sensitivity and a specificity of 90 %, and a detection limit of 1.5 nmol/l. The concordance rate between the HRG AuNPs assay with RT-PCR after RNA purification using magnetic nanoparticles was 93.3 %. The median follow-up period was 60 months. Among traditional prognostic biomarkers, HRG was a significant independent prognostic marker in relapse-free survival (RFS). HRG RNA is an independent prognostic marker for breast cancer and can be detected using gold NPs assay, which is rapid, sensitive, specific, inexpensive to extend the value for breast cancer prognosis.
KeywordsBreast carcinoma Tissue biomarkers Gold nanoparticles Histidine-rich glycoprotein Magnetic nanoparticles
- Her-2 neu
Human epidermal growth factor receptor 2
Modified magnet particles
This work was supported by the Egyptian Academy of Research and Technology, the Science and Technology Center, Project 21, and a grant from YJ-STRC to H. Azzazy. The authors acknowledge Mr. Kamel Eid from YJ-STRC for preparing the magnetic nanoparticles.
Conflict of interest
The authors declare that they have no competing interests.
- 2.Howlader, N., Noone, A.M., Krapcho, M. (2010) SEER Cancer statistics review,1975−2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.
- 3.Bhatt, A. N., Mathur, R., Farooque, A., Verma, A., & Dwarakanath, B. S. (2010). Cancer biomarkers – current perspectives. Indian Journal of Medical Research, 132, 129–149.Google Scholar
- 14.Pinder, S. E., Elston, C. W., & Ellis, I. O. (1998). Invasive carcinoma: usual histological types. In C. W. Elston & I. O. Ellis (Eds.), The breast (3rd ed., pp. 283–337). Edinburgh: Churchill Livingstone.Google Scholar
- 15.Sobin, L., Gospodarowicz, M., & Wittekind, C. (Eds.). (2009). TNM classification of malignant tumors (7th ed.). Hoboken: Wiley.Google Scholar
- 16.World Health Organization. (1969–1981) International histological classification of tumours. 2nd ed. Geneva: World Health Organization; Berlin: Springer-Verlag, 1988–Present.Google Scholar
- 17.Hummon, A. B., Lim, S. R., Difilippantonio, M. J., & Ried, T. (2007). Isolation and solubilization of proteins after TRIzol® extraction of RNA and DNA from patient material following prolonged storage. Bio Techniques Journal, 42, 467–472.Google Scholar
- 18.Sambrook, J., & Fritsch, E. F. (1989). Molecular cloning: a laboratory manual (2nd ed., pp. 42–59). New York: Cold Spring Harbor Laboratory Press.Google Scholar
- 22.Sabbatini, A. R. M., Battolla, M. B., Martini, P. E., Ranieri-Raggi, D. M., Moir, A. J. G., & Raggi, A. (2011). Evidence that muscle cells do not express the histidine-rich glycoprotein associated with AMP deaminase but can internalise the plasma protein. European Journal of Histochemistry, 55, e6.Google Scholar
- 26.Lianga, S., Singh, M., Gam, L., (2010/2011) Potential hydrophobic protein markers of breast cancer in Malaysian Chinese, Malay and Indian patients. Cancer Biomarkers, 8: 319–330 319.Google Scholar
- 27.Noh, S., Jung, J. J., Jung, M., Kim, K. H., Lee, H. Y., Wang, B., Cho, J., Kim, T. S., Jeung, H. C., & Rha, S. Y. (2012). Body fluid MMP-2 as a putative biomarker in metastatic breast cancer. Oncology Letters, 3, 699–703.Google Scholar
- 28.Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2012). Cancer incidence and mortality worldwideIARC Cancer Base No. 10. Lyon: International Agency for Research on Cancer.Google Scholar
- 32.Jung, M., Choi, E. H., Nam, C. M., Rha, S. Y., Jeung, H. C., Lee, S. H., Yang, W. I., Roh, J. K., & Chung, H. C. (2013). Application of the adjuvant! Online model to Korean breast cancer patients: an assessment of prognostic accuracy and development of an alternative prognostic tool. Annals of Surgical Oncology, 20, 2615–2624. doi: 10.1245/s10434-013-2956-z.CrossRefGoogle Scholar
- 33.Goud, T. M., Dwarakanath, B. S., Augustus, M., & Bhargava, K. M. (1995). Flow cytometry of breast tumors. Relevance to clinicopathology and survival. Analytical and Quantitative Cytology and Histology, 17, 265–271.Google Scholar
- 34.Cecchini, R. S., Costantino, J. P., Cauley, J. A., Cronin, W. M., Wickerham, D. L., Land, S. R., Weissfeld, J. L., & Wolmark, N. (2012). Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials. Cancer Prevention Research, 5, 583–592.CrossRefGoogle Scholar